Study to Assess the Efficacy, Safety and Tolerability of Laquinimod Compared to Placebo
Study Title
- A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
Teva Identifier
- TV5600-CNS-20006 | 2014-001579-30
ClinicalTrials.gov Identifier
- NCT02284568
Study Status
- Completed
Trial Condition(s)
- Primary Progressive Multiple Sclerosis
Interventions
- Drug: Placebo | Drug: Laquinimod
Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
Gender
- Female, Male
Age Range
- 25 Years to 55 Years
Trial Duration
- January 12, 2015 - October 1, 2017
Phase
- Phase 2
Study Type
Interventional
